Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699126 | 0.87 | CYP2D6 (0.48) | CHRM1CHRM3CHRM5CYP2D6KMT2A | |
| SCHEMBL13699331 | 0.85 | CHRM1 (0.39) | CHRM1CHRM3CHRM5CYP2D6KMT2A | |
| SCHEMBL4228368 | 0.80 | LPAR1 (0.39) | LPAR1LPAR5PTGIROPRM1OPRD1 | |
| SCHEMBL13699221 | 0.78 | CYP2D6 (0.40) | CHRM1CHRM3CHRM5CYP2D6KMT2A | |
| SCHEMBL4686937 | 0.78 | POLB (0.43) | KMT2ALPAR1LPAR5PTGIR | |
| SCHEMBL13699295 | 0.76 | CYP2D6 (0.37) | CHRM1CHRM3CHRM5CYP2D6KMT2A | |
| SCHEMBL4242218 | 0.75 | ACHE (0.42) | KMT2ALPAR1LPAR5PTGIR | |
| SCHEMBL13699207 | 0.75 | PKM (0.41) | CHRM1CHRM3CHRM5CYP2D6KMT2A | |
| SCHEMBL4234325 | 0.74 | ACHE (0.41) | KMT2ALPAR1LPAR5PTGIR | |
| SCHEMBL13699114 | 0.74 | CYP2D6 (0.45) | CYP2D6KMT2AOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | CHRM1 122/4885CHRM3 168/4885CHRM5 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.